Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy.
Francesco Paolo TambaroSajad Jawad KhazalCesar NunezDristhi RagoonananPriti TewariDemetrios PetropoulosPartow KebriaeiWilliam George WierdaKris Michael MahadeoPublished in: Clinical case reports (2020)
The T-cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T-cell therapy.